ULTRAGENYX PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.05 USD | -9.44% |
|
-5.68% | -18.34% |
| Jun. 14 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
| Jun. 14 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
Financials (USD)
| Sales 2024 * | 512M | Sales 2025 * | 618M | Capitalization | 3.53B |
|---|---|---|---|---|---|
| Net income 2024 * | -560M | Net income 2025 * | -492M | EV / Sales 2024 * | 6.44 x |
| Net cash position 2024 * | 236M | Net cash position 2025 * | 301M | EV / Sales 2025 * | 5.23 x |
| P/E ratio 2024 * |
-5.94
x | P/E ratio 2025 * |
-7.14
x | Employees | 1,276 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ultragenyx Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | -9.44% | ||
| 1 week | -5.68% | ||
| Current month | -2.72% | ||
| 1 month | -5.03% | ||
| 3 months | -17.56% | ||
| 6 months | -15.05% | ||
| Current year | -18.34% |
1 week
38.16
45.59
1 month
37.8245.59
Current year
37.8254.56
1 year
31.5254.56
3 years
31.52104.38
5 years
31.52179.65
10 years
31.52179.65
| Managers | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.21% | 1 M€ | +0.84% | - | |
| 0.82% | 4 M€ | +20.15% | ||
| 0.43% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 39.05 | -9.44% | 4,107,672 |
| 24-06-13 | 43.12 | -3.41% | 1,246,733 |
| 24-06-12 | 44.64 | +7.83% | 1,517,932 |
| 24-06-11 | 41.4 | -1.36% | 481,737 |
| 24-06-10 | 41.97 | +1.38% | 486,183 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Calendar
2024-06-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
39.05
USD
Average target price
90.05
USD
Spread / Average Target
+130.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.34% | 3.53B | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| +5.07% | 22.94B | |
| -12.75% | 22.22B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| -39.94% | 16.87B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- RARE Stock
